Skip to search formSkip to main contentSkip to account menu

Anti-BCMA Antibody-drug Conjugate GSK2857916

Known as: Anti-BCMA ADC GSK2857916, GSK2857916, J6M0-mcMMAF 
An antibody-drug conjugate (ADC) consisting of an afucosylated, humanized monoclonal antibody, directed against the B-cell maturation antigen (BCMA… 
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
PF558 THE ANTI-BCMA ANTIBODY-DRUG CONJUGATE GSK2857916 DRIVES IMMUNOGENIC CELL DEATH AND IMMUNE-MEDIATED ANTI-TUMOR RESPONSES, AND IN COMBINATION WITH AN OX40 AGONIST POTENTIATES IN VIVO ACTIVITY
2019
2019
PS1372 B-CELL MATURATION ANTIGEN ANTIBODY-DRUG CONJUGATE (ADC), GSK2857916, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL SAFETY, EFFICACY AND PHARMACOKINETIC (PK) ANALYSES FROM A PHASE I…
2018
2018
Targeting BCMA Achieves Deep and Durable Responses in Multiple Myeloma.
Targeting BCMA with the antibody-drug conjugate GSK2857916 is well tolerated in a phase I trial. 
Review
2017
Review
2017
OPTIMALISASI PENERAPAN BAR-CODE MEDICATION ADMINISTRATION (BCMA) SEBAGAI UPAYA PENINGKATAN KESELAMATAN PASIEN: LITERATUR RIVIEWOPTIMALISASI PENERAPAN BAR-CODE MEDICATION ADMINISTRATION (BCMA) SEBAGAI…
Pendahuluan: Keselamatan pasien merupakan bagian yang harus diupayakan dalam peningkatan mutu  pelayanan kesehatan di rumah sakit… 
2016
2016
ASH 2015: Von der Jahrestagung der amerikanischen Hämatologen
Für Patienten mit therapieresistenten B-Zell-Malignomen ist eine allogene Stammzelltransplantation die einzige kurative Option… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)